Haemonetics (HAE)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$102.92+0.07%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · HAE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 0.3% |
| Our one-year growth estimate | diamond | 6.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 5.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
HAE — officer change
Dated 2026-05-01
Director — Charles J. Dockendorff: Mr. Dockendorff will not stand for re-election at the Company’s 2026 Annual Meeting.
Why it matters: Organic revenue growth shows how well the company is expanding its core business. A growth rate of 4-7% aligns with management's guidance.
Supportive ifOrganic revenue growth for Q2 fiscal 2027 is reported above 5%.
Worry ifOrganic revenue growth for Q2 fiscal 2027 is reported below 4%.
Why it matters: This growth rate confirms that Haemonetics is on track to meet its raised guidance for fiscal 2027.
Supportive ifQ2 organic revenue growth reported at or above 5.9%.
Worry ifQ2 organic revenue growth is below 5.9%.
Why it matters: Progress on this program can affect shareholder value and how the market sees it.
Supportive ifCompany says it has finished a big part of the share repurchase program.
Worry ifCompany gives no updates or has delays in the share repurchase program.
Why it matters: If it drops below 4%, it shows growth problems. This may hurt investor trust.
Worry ifFiscal 2027 organic revenue growth reported at 4% or higher.
Less concerning ifFiscal 2027 organic revenue growth is below 4%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$142 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $314 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,006 loss on $10,000 · 40.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop in revenue growth would signal weakening demand in a growing sector.
Worry ifQ4 revenue growth reported below 5% year over year.
Less concerning ifQ4 revenue growth stays above 5% year over year.
Why it matters: This call will provide insights on performance and guidance. Key metrics will be discussed.
Watch forManagement shares good news and guidance during the earnings call.
Also watch forManagement gives bad news or shares poor results during the earnings call.
Why it matters: Martin Madaus has a lot of experience. His work could improve strategy and operations.
Watch forGood changes in strategy or operations are linked to Madaus.
Also watch forNo clear improvements or bad results after his election.
Why it matters: Stable leaders help guide the company. Changes can affect how investors feel and plan.
Worry ifA new executive hire was announced. This will make the leadership stronger.
Less concerning ifMore executives are leaving. There are also issues with leadership.
Why it matters: This expansion is crucial for Haemonetics to meet its fiscal 2027 margin goals.
Supportive ifAdjusted operating margin grows by 50-100 basis points from last year.
Worry ifAdjusted operating margin does not grow or gets smaller from last year.
Why it matters: A bigger operating margin shows the company can control costs. A margin over 17% means progress.
Supportive ifThe operating margin for Q2 fiscal 2027 is above 17%.
Worry ifOperating margin for Q2 fiscal 2027 is below 16.9%.
Why it matters: This level shows Haemonetics is handling cash and investments well.
Supportive ifFree cash flow conversion reported at or near 80%.
Worry ifFree cash flow conversion reported below 80%.
Why it matters: This margin expansion is important for profitability. It shows how well the company is managing costs.
Supportive ifOperating margin expands by 75 bps or more YoY.
Worry ifOperating margin expands less than 50 bps YoY.
Why it matters: A drop in sector revenue growth may show bigger problems for Haemonetics.
Worry ifSector revenue growth reported below its median year over year.
Less concerning ifSector revenue growth remains above its median year over year.